Loading
A phase 3 trial of Filgrastim in multiple myeloma, run by BioLineRx, Ltd., active and no longer recruiting.
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) is a phase 3 interventional study registered as NCT03246529 by BioLineRx, Ltd., with 180 participants enrolled, started 2018-03-23 and due to reach its primary completion in 2020-12-22. Interventions recorded: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares BioLineRx, Filgrastim (G-CSF), Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Growth factors: G-CSF and febrile neutropenia prevention, Filgrastim (G-CSF).
Shares Growth factors: G-CSF and febrile neutropenia prevention, Filgrastim (G-CSF).
Shares BioLineRx, Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Growth factors: G-CSF and febrile neutropenia prevention, Filgrastim (G-CSF).